Repositioning Candidate Details
| Candidate ID: | R0510 |
| Source ID: | DB01392 |
| Source Type: | approved; investigational; vet_approved |
| Compound Type: | small molecule |
| Compound Name: | Yohimbine |
| Synonyms: | (+)-yohimbine; (16α,17α)-17-hydroxyyohimban-16-carboxylic acid methyl ester; 17α-hydroxyyohimban-16α-carboxylic acid methyl ester; Yohimbic acid methyl ester; Yohimbine |
| Molecular Formula: | C21H26N2O3 |
| SMILES: | [H][C@@]12CC[C@H](O)[C@H](C(=O)OC)[C@@]1([H])C[C@]1([H])N(CCC3=C1NC1=CC=CC=C31)C2 |
| Structure: |
|
| DrugBank Description: | A plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of impotence. It is also alleged to be an aphrodisiac. |
| CAS Number: | 146-48-5 |
| Molecular Weight: | 354.4427 |
| DrugBank Indication: | Indicated as a sympatholytic and mydriatic. Impotence has been successfully treated with yohimbine in male patients with vascular or diabetic origins and psychogenic origins. |
| DrugBank Pharmacology: | Yohimbine is an indolalkylamine alkaloid with chemical similarity to reserpine. Yohimbine blocks presynaptic alpha-2 adrenergic receptors. Its action on peripheral blood vessels resembles that of reserpine, though it is weaker and of short duration. Yohimbine's peripheral autonomic nervous system effect is to increase parasympathetic (cholinergic) and decrease sympathetic (adrenergic) activity. It is to be noted that in male sexual performance, erection is linked to cholinergic activity and to alpha-2 adrenergic blockade which may theoretically result in increased penile inflow, decreased penile outflow or both. Yohimbine exerts a stimulating action on the mood and may increase anxiety. Such actions have not been adequately studied or related to dosage although they appear to require high doses of the drug. Yohimbine has a mild anti-diuretic action, probably via stimulation of hypothalmic center and release of posterior pituitary hormone. Reportedly Yohimbine exerts no significant influence on cardiac stimulation and other effects mediated by (beta)-adrenergic receptors. Its effect on blood pressure, if any, would be to lower it; however, no adequate studies are at hand to quantitate this effect in terms of Yohimbine dosage. |
| DrugBank MoA: | Yohimbine is a pre-synaptic alpha 2-adrenergic blocking agent. The exact mechanism for its use in impotence has not been fully elucidated. However, yohimbine may exert its beneficial effect on erectile ability through blockade of central alpha 2-adrenergic receptors producing an increase in sympathetic drive secondary to an increase in norepinephrine release and in firing rate of cells in the brain noradrenergic nuclei. Yohimbine-mediated norepinephrine release at the level of the corporeal tissues may also be involved. In addition, beneficial effects may involve other neurotransmitters such as dopamine and serotonin and cholinergic receptors. |
| Targets: | Alpha-2A adrenergic receptor antagonist; Alpha-2B adrenergic receptor antagonist; Alpha-2C adrenergic receptor antagonist; 5-hydroxytryptamine receptor 1A partial agonist; 5-hydroxytryptamine receptor 1B partial agonist; 5-hydroxytryptamine receptor 1D partial agonist; Dopamine D2 receptor antagonist; Dopamine D3 receptor antagonist; 5-hydroxytryptamine receptor 2A antagonist; 5-hydroxytryptamine receptor 2C antagonist; ATP-sensitive potassium channel inhibitor; 5-hydroxytryptamine receptor 2B antagonist |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|